Search Medications (Drugs):
Medications (Drugs) from A to Z:
Home > Medications (Drugs) > Meprobamate > More information about Meprobamate

More information about Meprobamate


(me proe BA mate)

U.S. Brand Names




Generic Available


Canadian Brand Names



Management of anxiety disorders

Use - Dental

Treatment of muscle spasm associated with acute temporomandibular joint pain; management of dental anxiety disorders

Use - Unlabeled/Investigational

Demonstrated value for muscle contraction, headache, premenstrual tension, external sphincter spasticity, muscle rigidity, opisthotonos-associated with tetanus



Pregnancy Risk Factor



Enters breast milk/not recommended


Hypersensitivity to meprobamate, related compounds (including carisoprodol), or any component of the formulation; acute intermittent porphyria; pre-existing CNS depression; narrow-angle glaucoma; severe uncontrolled pain; pregnancy


Physical and psychological dependence and abuse may occur; abrupt cessation may precipitate withdrawal. Use with caution in patients with depression or suicidal tendencies, or in patients with a history of drug abuse. May cause CNS depression, which may impair physical or mental abilities. Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Effects with other sedative drugs or ethanol may be potentiated. Not recommended in children <6 years of age; allergic reaction may occur in patients with history of dermatological condition (usually by fourth dose). Use with caution in patients with renal or hepatic impairment, or with a history of seizures. Use caution in the elderly as it may cause confusion, cognitive impairment, or excessive sedation.

Adverse Reactions

Frequency not defined.

Cardiovascular: Syncope, peripheral edema, palpitation, tachycardia, arrhythmia

Central nervous system: Drowsiness, ataxia, dizziness, paradoxical excitement, confusion, slurred speech, headache, euphoria, chills, vertigo, paresthesia, overstimulation

Dermatologic: Rashes, purpura, dermatitis, Stevens-Johnson syndrome, petechiae, ecchymosis

Gastrointestinal: Diarrhea, vomiting, nausea

Hematologic: Leukopenia, eosinophilia, agranulocytosis, aplastic anemia

Neuromuscular & skeletal: Weakness

Ocular: Blurred vision, impairment of accommodation

Renal: Renal failure

Respiratory: Wheezing, dyspnea, bronchospasm, angioneurotic edema


Symptoms of overdose include drowsiness, lethargy, ataxia, coma, hypotension, shock, and death. Treatment is supportive following attempts to enhance drug elimination.

Drug Interactions

CNS depressants: Sedative effects may be additive with other CNS depressants; monitor for increased effect; includes barbiturates, benzodiazepines, narcotic analgesics, ethanol, and other sedative agents

Ethanol/Nutrition/Herb Interactions

Ethanol: Avoid ethanol (may increase CNS depression).

Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).

Mechanism of Action

Affects the thalamus and limbic system; also appears to inhibit multineuronal spinal reflexes


Onset of action: Sedation: ~1 hour

Distribution: Crosses placenta; enters breast milk

Metabolism: Hepatic

Half-life elimination: 10 hours

Excretion: Urine (8% to 20% as unchanged drug); feces (10% as metabolites)



Children 6-12 years: Anxiety: 100-200 mg 2-3 times/day

Adults: Anxiety: 400 mg 3-4 times/day, up to 2400 mg/day

Dosing interval in renal impairment:  

Clcr 10-50 mL/minute: Administer every 9-12 hours

Clcr<10 mL/minute: Administer every 12-18 hours

Hemodialysis: Moderately dialyzable (20% to 50%)

Dosing adjustment in hepatic impairment:   Probably necessary in patients with liver disease

Monitoring Parameters

Mental status

Reference Range

Therapeutic: 6-12 mcg/mL (SI: 28-55
mol/L); Toxic: >60 mcg/mL (SI: >275

Patient Education

Take exactly as directed; do not increase dose or frequency. Drug may cause physical and/or psychological dependence. Do not use alcohol or other prescription or OTC medications (especially pain medications, sedatives, antihistamines, or hypnotics) without consulting prescriber. Maintain adequate hydration (2-3 L/day of fluids) unless instructed to restrict fluid intake. You may experience drowsiness, lightheadedness, impaired coordination, dizziness, or blurred vision (use caution when driving or engaging in tasks requiring alertness until response to drug is known); nausea, vomiting, or dry mouth (small, frequent meals, frequent mouth care, chewing gum, or sucking lozenges may help); or diarrhea (boiled milk, yogurt, or buttermilk may help). Report persistent CNS effects, skin rash or irritation, changes in urinary pattern, wheezing or respiratory difficulty, or worsening of condition. Pregnancy/breast-feeding precautions:   Do not get pregnant while taking this medication; use appropriate contraceptive measures. Breast-feeding is not recommended.

Nursing Implications

Assist with ambulation; monitor mental status

Additional Information

Withdrawal should be gradual over 1-2 weeks. Benzodiazepine and buspirone are better choices for treatment of anxiety disorders.

Anesthesia and Critical Care Concerns/Other Considerations

Withdrawal should be gradual over 1-2 weeks. Benzodiazepines and buspirone are better choices for treatment of anxiety disorders.

Dental Health: Effects on Dental Treatment

No significant effects or complications reported

Dental Health: Vasoconstrictor/Local Anesthetic Precautions

No information available to require special precautions

Dosage Forms

Tablet: 200 mg, 400 mg


Hassan E, "Treatment of Meprobamate Overdose With Repeated Oral Doses of Activated Charcoal,"Ann Emerg Med, 1986, 15(1):73-6.

Jacobsen D, Wiik-Larsen E, Saltvedt E, et al, "Meprobamate Kinetics During and After Terminated Hemoperfusion in Acute Intoxications,"J Toxicol Clin Toxicol, 1987, 25(4):317-31.

Volturo GA, "Meprobamate and Bezoar Formation,"Ann Emerg Med, 1987, 16(4):472-3.

International Brand Names

Andaxin® (HU); Cyrpon® (AT); Dapaz® (ES); Epikur® (AT); Equanil® (FR, ZA); Meprobamat® (DE, GB, RO); Méprobamate Richard® (FR); Meprobamat-Petrasch® (AT); Meprobamat Pliva® (HR); Mepro® (BE, IL); Meprodil® (CH); Microbamat® (AT); Miltaun® (AT); Novo-Mepro (CA); Oasil® (LU); Pertranquil® (BE, LU); Praol® (GR); Probamyl® (BE); Procalmadiol® (LU); Quaname® (LU); Quanil® (IT); Reposo-Mono® (BE); Sanobamat® (BE); Tranquilin® (LU); Visano® (DE)